Australia (AU)

Consensus statement on the problem of terminology in psychological interventions using the internet or digital components (2020) Smoktunowicz E, Barak A, Andersson G, Banos RM, Berger T, Botella C, Dear BF, et al. Journal article Induced Photon Correlations Through the Overlap of Two Four-Wave Mixing Processes in Integrated Cavities (2020) Zhang Y, Kues M, Roztocki P, Reimer C, Fischer B, Maclellan B, Bisianov A, et al. Journal article Chalcogenide fibers for kerr squeezing (2020) Anashkina EA, Andrianov A, Corney JF, Leuchs G Journal article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article CROSSED PRODUCTS OF C*-ALGEBRAS FOR SINGULAR ACTIONS WITH SPECTRUM CONDITIONS (2020) Grundling H, Neeb KH Journal article Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2020) Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, et al. Conference contribution EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020) Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al. Conference contribution Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) (2020) Fasching P, Delea T, Lu YS, Deboer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Conference contribution Latency and Reliability of mmWave Multi-Hop V2V Communications Under Relay Selections (2020) Li Z, Xiang L, Ge X, Mao G, Chao HC Journal article